explore -WSS

explore

author：explore 2025-09-07 11:14:34 - browse：298

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

Health AI adoption puts security, privacy startups on investors' radar

American TikTok star stuck in Dubai for months following rental car altercation

Neuroscience’s long legacy of racism

What AstraZeneca

Physicians and social media: If you see something, say something?

5 wounded, 2 critically, in Michigan shopping center shooting

leisure time

explore

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Health AI adoption puts security, privacy startups on investors' radar

How one medical school became remarkably diverse

Future doctors should be trained to promote social change

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Methadone treatment changes are coming. Do they go far enough?

Dobbs anniversary: the lost opportunity of abortion as health care

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Creating egg and sperm cells from stem cells raises ethical issues

explore

Neuroscience’s long legacy of racism

What AstraZeneca

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Russian and Belarusian players banned from a women's tennis tournament in Prague

Orchard's therapy for neuron disease in children wins FDA approval

Neuroscience’s long legacy of racism

Wikipedia

knowledge

explore

leisure time